ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions
  • Abstract Number: 1421

    Differential Impact of B-cell Targeted Monotherapy and Combination Regimen on the Peripheral Blood Transcriptome of Adults with Active Sjögren Disease
  • Abstract Number: 1422

    Evaluation of Salivary Gland Focus Score in Sjogren’s Disease Using Deep Learning: A Step Towards Tissue Biomarker Discovery
  • Abstract Number: 1423

    An Observational Analytical Study on HCV Patients with Sicca Manifestations Before and After Direct-Acting Antivirals in Comparison with Sjogren’s Disease; Infection versus Autoimmunity
  • Abstract Number: 1424

    Associations of Human Leukocyte Antigens (HLA) Class II with Interstitial Lung Disease (ILD) in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs). A Prospective Study in Sequential Patients with SARD-ILD
  • Abstract Number: 1425

    Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic
  • Abstract Number: 1426

    Single Cell RNA-Seq Characterization of Circulating Immune Cells in Sjogren’s Syndrome: Comparison to SLE and Rheumatoid Arhtritis
  • Abstract Number: 1427

    Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study
  • Abstract Number: 1428

    A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)
  • Abstract Number: 1429

    Association of Bone Erosion and Microarchitecture with Disease Activity and Damage in Sjögren’s Disease
  • Abstract Number: 1430

    C57BL/6.NOD-Aec1Aec2 Mice Recapitulate Sjögren’s Serology Better Than NOD.B10Sn-H2b Models and JAK Inhibitor Treatment Improves Immunoglobulins and Salivary Gland Inflammation but Not Salivary Flow in Sjögren’s Mice
  • Abstract Number: 1431

    Computational Systems Biology Approach to Unveil Molecular Interactions in Sjogren’s Disease Pathogenesis
  • Abstract Number: 1432

    Diagnostic Performance of Mayor Salivary Gland Ultrasound for Diagnosis of Sjögren’s Syndrome in Routine Clinical Practice
  • Abstract Number: 1433

    Association of Contextual Factors with Sonographic Inflammatory and Structural Phenotypes in Psoriatic Arthritis Patients
  • Abstract Number: 1434

    Prevalence of Liver Steatosis in Axial Spondyloarthritis : A Retrospective Study Using Computed Tomography Liver Minus Spleen Attenuation Ratio
  • Abstract Number: 1435

    Prevalence, Progression, and Associated Factors of Enthesopathy at Hip and Pelvic Regions in Patients with Axial Spondyloarthritis: Computed Tomography-based Assessment
  • « Previous Page
  • 1
  • …
  • 96
  • 97
  • 98
  • 99
  • 100
  • …
  • 182
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology